Immunocore Holdings: Sustained Growth and Promising Pipeline Drive Positive Outlook

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Immunocore Holdings (IMCR – Research Report). The associated price target is $60.00.

Tyler Van Buren’s rating is based on the consistent growth and promising future prospects of Immunocore Holdings. The company reported Kimmtrak sales of $84.1 million for the fourth quarter, which aligns with market expectations and marks the eleventh consecutive quarter of growth. This growth is largely driven by increased demand in the U.S. and ongoing global expansion, with the company achieving significant market penetration and planning further growth through community expansion and additional international launches.
Furthermore, Immunocore’s pipeline shows potential with ongoing trials and data presentations. The company’s brenetafusp (Brene) has shown promising results in various trials, including those for melanoma and ovarian cancer, suggesting it could offer survival benefits similar to Kimmtrak. The broad expression of the PRAME target across many solid tumors also indicates a substantial market opportunity, reinforcing the positive outlook for Immunocore’s future growth and development.